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Background: Immunohistochemistry using antibody cocktails against basal cell specific and cancer-associated
markers is important in the diagnosis of prostate carcinoma in needle biopsies. We compared the usefulness for
detecting prostate carcinoma of a three-marker cocktail of antibodies to α-methylacyl-CoA racemase (AMACR), p63
and cytokeratin (CK) 5 with a traditional two-marker cocktail of AMACR and p63.
Methods: Sixty-six prostate needle biopsies were analysed prospectively. Serial sections were immunostained with
the two- and three- antibody cocktails. Blinded slides were assessed individually by two pathologists and sensitivity,
specificity and kappa statistics were calculated.
Results: Both antibody cocktails contributed to the detection of prostate carcinoma in needle biopsies. There was
an acceptable level of agreement between the pathologists for both the cocktails. Sensitivity was similar for one
pathologist comparing both the cocktails (76.4% and 75.7%), but was slightly lower comparing the three-antibody
with the two-antibody cocktail for the other pathologist (66.6% vs. 77.4%, respectively). Higher specificity values of
90.3% were achieved by both pathologists using three-antibody as compared with two-antibody cocktails (68.7%
and 71.8%).
Conclusions: Antibody cocktails are important in diagnosing prostate carcinoma in needle biopsies. Adding an
extra basal cell marker to the traditional two-antibody cocktail improves the specificity of detecting prostate
carcinoma in limited needle biopsy material, and should be considered for routine diagnostic use.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2492231327330327
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Prostate cancer is globally the second most frequently
diagnosed cancer and the sixth leading cause of cancer
death in males, accounting for 14% (903,500) of new
cancer cases and 6% (258,400) of cancer deaths in males
in 2008 [1]. Incidence rates vary by more than 25-fold
worldwide, with the highest rates recorded primarily in
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reproduction in any medium, provided the orAmerica, largely because of the widespread use of
prostate-specific antigen (PSA) testing and subsequent
prostate biopsy in these regions [1].
Histological diagnosis of prostatic cancer is usually
based on histological evaluation of prostatic needle biop-
sies. This can be challenging, particularly when the ma-
lignant tissue is limited and is admixed with benign
prostatic glands, or because of the presence of benign
mimickers of malignancy such as atypical adenomatous
hyperplasia (adenosis), atrophy, basal cell hyperplasia,
nephrogenic adenoma, seminal vesicles or Cowpers
glands [2-4]. In this setting, immunohistochemistry maytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and is used routinely in many pathology laboratories.
Whilst a wide variety of immunohistochemical markers
have been proposed for this purpose, antibodies against
two classes of prostatic biomarkers are most commonly
used; firstly, basal epithelial cell-specific markers and
secondly, prostate carcinoma-specific markers.
It is widely accepted that absence of basal cells is an
important histological criterion for prostate carcinoma.
Thus, lack of basal cell staining provides immunohisto-
chemical support for a malignant diagnosis in atypical
prostatic lesions [3]. The most commonly used basal cell
markers are the high-molecular-weight cytokeratins
(such as 34βE12, cytokeratin (CK) 5, CK5/6 and CK14)
and p63 [2]. CK 5 is an intermediate-sized cytokeratin
that is typically expressed in the basal cells of benign
prostate glands, where it shows continuous cytoplasmic
staining of the deep layer of the prostate epithelium [5].
p63 is selectively expressed in the basal cell compart-
ment of various epithelial tissues and serves as a sensi-
tive immunohistological target for identifying the nuclei
of basal cells in benign prostatic lesions [3].
Several molecules have been proposed as positive
immunohistological markers of prostatic carcinoma, in-
cluding α-methylacyl coenzyme A racemase (AMACR or
P504S) and Prostate Tumour Overexpressed-1 (PTOV1)
[6]. Of these, the most widely used is AMACR, which is
expressed in 80% - 100% of prostatic adenocarcinomas
[7]. However, staining for AMACR alone is of limited
value as a positive cancer marker, since it is often also
expressed in high grade prostatic intraepithelial neopla-
sia (PIN), in atypical adenomatous hyperplasia (adenosis)
and even in atrophic or benign glands [3,7,8]. However,
combined staining for a basal cell marker and for
AMACR (usually in the form of a two-antibody cocktail)
has proved to be an useful immunohistochemical tool
for evaluating difficult prostate needle biopsies [9-11]
and this type of double staining is widely used in the
routine diagnostic setting. For example, in our labora-
tory we use routinely a two-marker cocktail containing
an antibody against p63 (our principal basal cell marker)
and an antibody against AMACR, as an immunohisto-
chemical supplement to standard haematoxylin and
eosin (H&E) staining when assessing difficult prostatic
needle biopsies.
Previous studies have suggested that two basal cell
markers may be stained together with AMACR in a
triple-antibody cocktail, further improving the ability to
recognise limited prostatic carcinoma foci [3,9]. This
prompted us to include an antibody to CK5 as an add-
itional basal cell-specific marker to p63 in our routine
immunohistological cocktail, and to evaluate these three
(AMACR/p63/CK5) and two-marker (AMACR/p63)
combinations in a diagnostic setting.Methods
Sixty-six prostate needle biopsies received prospectively
between January 2011 and June 2011 at the Institute of
Pathology, Aarhus University Hospital, Denmark were
included in this study. Following standard diagnostic
H&E staining, two parallel 4 μm serial paraffin sections
were cut from the biopsies for immunostaining with
either our traditional two-marker antibody cocktail
(AMACR and p63) or the three-marker combination
(AMACR, p63 and CK5).
Immunohistochemistry
The immunohistochemical stains were optimized and
tested for specificity using prostate controls including
areas of normal tissue, and both benign and malignant
disease (data not shown). In the studies, internal con-
trols were present in most biopsies examined. External
positive tissue controls were included in each round of
stains.
Traditional two-marker cocktail
Deparaffinized sections for the two-marker combination
were stained in a standard Ventana BenchMark XT
automatic stainer using ultraView Universal DAB Detec-
tion Kit (Ventana Medical Systems, Tucson, AZ),
according to the manufacturer. In brief, sections were
demasked with Cell Conditioner buffer for 8 minutes
and endogenous peroxidase was blocked with ultraView
inhibitor. The two-marker cocktail containing primary
antibodies to AMACR (monoclonal rabbit anti-AMACR,
clone 13 H4, Dako, Glostrup, Denmark; dilution 1:100)
and p63 (monoclonal mouse anti-human p63, clone
4A4, Dako; dilution 1:300) was applied for 30 minutes.
Sections were then incubated with ultraView Horse Rad-
ish Peroxidase (HRP) Multimer, containing a mixture of
HRP-labelled goat anti-mouse and anti-rabbit anti-
bodies. Bound antibodies were visualized by incubation
in ultraView hydrogen peroxide substrate and DAB
chromogen. Positive signals result in a brown colour re-
action in the nuclei of benign basal epithelial cells (p63)
and in the cytoplasm of malignant prostate epithelial cell
cytoplasm (AMACR).
Novel three-marker cocktail
Epitope retrieval was achieved by incubating deparaffi-
nised sections in TEG buffer, pH 9 in a microwave at 800
Watts for 8 minutes. Sections were stained on a LabVi-
sion Autostainer (Lab Vision, Runcorn, UK). The follow-
ing primary antibodies were used in a triple-cocktail,
applied for 40 minutes: CK5 (rabbit monoclonal anti-
CK5, clone EP1601Y, Epitomics, Catalog nr. 1988–1; di-
lution 1:400), p63 (mouse monoclonal anti-p63, clone
4A4, Dako, code M7247; dilution 1:23) and AMACR
(mouse monoclonal anti-AMACR, clone (2A10F3):
Figure 1 Immunohistochemical staining of a needle biopsy
containing normal prostate tissue with the two-marker cocktail.
Benign basal epithelial cells show dark brown nuclear staining for
p63. There is no positive staining for AMACR (x 200).
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Bound antibody signals were detected by incubation in
polymers for 30 minutes; first with a horse radish peroxi-
dise (HRP) conjugated polymer against the mouse anti-
bodies and then with an alkaline phosphatase (AP)
conjugated polymer against the rabbit antibody. Signals
were developed using separate chromogens, DAB for the
HRP-linked polymer (brown) and Permanent Red for the
AP-linked polymer (red). Thus, benign basal prostatic
epithelial cells were stained brown in their nuclei (p63)
and red in their cytoplasm (CK5), while malignant pros-
tatic carcinoma cells were stained brown in their cyto-
plasm (AMACR).
The immunostained slides were blinded and then evalu-
ated separately by two pathologists, the first an experi-
enced senior uropathologist, and the second a less
experienced junior pathologist. Immunostained slides
were evaluated independently of the H&E stained sec-
tions. Positive immunohistochemical staining was defined
as clear, discrete staining of either the nucleus (p63) or
the cytoplasm (CK 5 and AMACR). The two- and three-
marker antibody cocktail stains for each biopsy were
recorded as giving one of three possible results: 1. benign,
2. intra-epithelial neoplasia or 3. malignant.
Specificity and sensitivity values were calculated for
both the two- and three-marker cocktails for each path-
ologist, compared with a consensus diagnosis based on
final evaluation of the H&E and all immunostains. When
calculating specificity and sensitivity, results were desig-
nated into one of two categories: 1. test negative/condition
absent (including all biopsies scored as benign) or test
positive/condition present (including all biopsies scored as
either intra-epithelial neoplasia or malignant). Kappa
statistics were calculated for each pathologist using the
two- and three-marker cocktails for each of the three cat-
egories benign, intra-epithelial neoplasia and malignant.
The study was conducted with the ethical board ap-
proval from the relevant authorities in Denmark.Results
Final diagnoses are not shown in detail, but included a
range of benign prostatic disease (32 biopsies), intra-
epithelial neoplasia (4 biopsies) and prostatic carcinomas
(30 biopsies). All carcinomas were of usual acinar type.Figure 2 Immunohistochemical staining of a needle biopsy
containing prostatic carcinoma with the two-marker cocktail.
Malignant glands show brown granular cytoplasmic staining pattern
for AMACR. Absent nuclear p63 signal indicates loss of basal
epithelia cells (x 100).Immunohistochemistry
Traditional two-marker cocktail
Benign prostatic glandular tissue showed strong dark
brown nuclear staining for p63 in basal cells without any
cytoplasmic AMACR staining in the glands [Figure 1]. In
contrast, areas of prostatic adenocarcinoma showed ab-
sent nuclear p63 staining due to loss of basal epithelial
cells, together with the gain of brown granular cytoplasmicstaining indicating expression of AMACR in malignant
glands [Figure 2].
Areas of PIN exhibited both brown cytoplasmic granu-
lar AMACR staining in the luminal epithelial cells and
dark brown nuclear p63 staining in the associated par-
tially fragmented basal cell layer, thus giving a character-
istic positive reaction for both markers in the same
glands [Figure 3].
Novel three-marker cocktail
Benign prostate tissue typically showed both dark brown
nuclear (p63) with red cytoplasmic (CK 5) staining in
basal cells (sometimes only one basal cell marker was
positive), with absent cytoplasmic positivity for AMACR
Figure 3 Immunohistochemical staining of a needle biopsy
containing an area of prostatic intra-epithelial neoplasia (PIN)
with the two-marker cocktail. Prostate glands show staining both
in the cytoplasm of luminal epithelial cells (brown granular
AMACR-positive staining) and in the nuclei of basal epithelial cells
(brown nuclear p63-positive staining). This reaction pattern is
characteristic for PIN (x 100).
Figure 5 Immunohistochemical staining of a needle biopsy
containing prostatic carcinoma with the three-marker cocktail.
Malignant glands show a brown granular cytoplasmic staining
pattern for AMACR with loss of basal epithelia cells (left-hand side).
A limited area of benign glandular tissue can be seen on the
right-hand side, showing preserved basal epithelial cells with
dark brown p63 nuclear staining and red CK5 cytoplasmic
staining (x 400).
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adenocarcinoma, nuclear and cytoplasmic staining for
p63 and CK5, respectively, was absent due to loss of
basal cells, whilst the malignant glands showed gain of
brown cytoplasmic granular staining indicating expres-
sion of AMACR [Figure 5].
Areas of PIN showed both brown cytoplasmic granular
AMACR staining in the luminal cells and dark brown
nuclear (p63) and/or red cytoplasmic (CK 5) staining
in partially preserved glandular basal epithelial cells
[Figure 6].Figure 4 Immunohistochemical staining of a needle biopsy
containing normal prostate tissue with the three-marker
cocktail. Benign basal epithelial cells show both dark brown nuclear
staining for p63 and red cytoplasmic staining for CK5. Luminal
epithelial cells show no positive staining for AMACR (x 200).Comparative evaluation of immunohistochemical cocktails
Both observers found that evaluation of the immunohis-
tological stains with the two cocktails was quick and
easy to perform. The pathologists had similar kappa
values assessing the biopsies, both using the two-marker
(κ= 0.6202) and three-marker (κ= 0.6349) cocktails.
For the junior pathologist, sensitivity and specificity
values were 75.7% and 71.8%, respectively, using the
two-marker cocktail and 76.4% and 90.3%, respectively,Figure 6 Immunohistochemical staining of a needle biopsy
containing an area of prostatic intra-epithelial neoplasia (PIN)
with the three-marker cocktail. Prostate glands show staining in
both the cytoplasm of luminal epithelial cells (brown granular
AMACR-positive) and in the basal epithelial cells (brown nuclear
p63-positive as well as red cytoplasm CK5-positive), characteristic for
PIN (x 400).
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ity and specificity values for the senior pathologist were
77.4% and 68.7%, respectively using the two-marker cock-
tail, and 66.6% and 90.3%, respectively with the three-
marker combination.
Discussion
Immunohistochemistry for basal cell-specific and cancer-
associated markers is valuable in the histopathological diag-
nosis of prostate carcinoma in needle biopsies [2,3]. For
example, positive AMACR staining helps identify areas of
carcinoma, whilst high molecular-weight CKs and the p63
transcription factor aid the search for normal basal cells
that are typically absent in malignant prostatic glands.
However, using single markers to diagnose prostate carcin-
oma is of limited use. For example, AMACR may also be
expressed in high grade PIN, in atypical adenomatous
hyperplasia (adenosis) and even in atrophic or benign
glands [3,7]. Moreover, the distribution of basal cells can be
patchy in both normal glands and in some benign lesions
that mimic prostate cancer, such as areas of atrophy, post-
atrophic hyperplasia, and atypical adenomatous hyperplasia
(adenosis) [7]. Furthermore, a diagnosis that is reliant on
the absence of an immunohistochemical reaction is inher-
ently less reliable. Indeed, a variety of technical problems,
including excessive formalin fixation [12], may lead to false
negative staining of normal basal cells.
The importance of these immunohistochemical and
technical pitfalls in interfering with accurate diagnosis can
be reduced by combined staining of prostate biopsies for
both positive and negative cancer markers using antibody
cocktails. Typically, these cocktails include AMACR to-
gether with either an antibody to high molecule-weight CK
or to p63. Study by Trpkov et al. demonstrated that CK5/6
is an excellent and dependable basal cell marker when used
in combination with AMACR; and CK 5/6 exhibited excel-
lent specificity for prostate cancer, which uniformly lacked
CK5/6 staining [5] . Some workers have gone further by in-
cluding an additional marker for basal cells in three-
marker cocktails, in order to try to improve the precision
of prostate carcinoma diagnosis in limited biopsy material.
Thus, Jiang and co-workers used immunohistochemistry
with a triple-antibody cocktail (containing antibodies to
AMACR, high molecule-weight 34βE12, and p63) to iden-
tify small, focal prostate carcinomas with high sensitivity
and complete specificity [9]. Similarly, Ng and colleagues
used the same triple-cocktail in a tissue microarray study
to identify prostate carcinoma with improved sensitivity
(93.8%) and specificity (100%), compared with using the
three antibodies individually [3].
Our study supports these previous findings. In addition,
we show for the first time that antibody to the high
molecular-weight CK5 can be successfully incorporated in
triple cocktails together with AMACR and p63. CK5 iswidely used as a robust immunohistochemical marker
for, amongst other things, basal epithelial cells. Thus,
antibodies to CK5 are widely available as routine markers
in diagnostic pathology laboratories, and can easily be
included in immunohistochemical protocols using auto-
matic staining machines. Although high molecular-
weight 34βE12 is included in antibody cocktails for
diagnosing prostate carcinoma, there are potential draw-
backs associated with the use of this marker. For ex-
ample, 34βE12 antibody reacts with a wide variety of CKs
including not only CK1, CK5, CK10 and CK14, but also
an undefined CK that may stain at least some complex
epithelia. Thus, 34βE12 may stain breast secretory cells
and ductal carcinoma in situ of the breast (which are
negative with CK5 antibody), hampering the use of the
antibody for the identification of CK5 and myoepithelial
cells in the breast [13]. Although this type of reaction has
not been reported as occurring in the prostate, any de-
gree of uncertainty about the specificity of a diagnostic
antibody is worrying. Similarly p63 when used individu-
ally demonstrated loss of immunostaining intensity in
stored slides and showed spurious cytoplasmic staining
of the luminal cells when used in low dilutions [5].
In our study, similar kappa values were found for both
the two-marker and the three-marker cocktails when
used by both pathologists, indicating fairly good agree-
ment between them for both cocktails. Both pathologists
were equally comfortable evaluating the results of both
antibody combinations. In the case of the three-marker
cocktail, usage of red staining for CK5 and brown staining
for both p63 and AMACR proved to be technically feas-
ible as well as provided a good contrast for interpretation.
Both observers had similar sensitivity levels for cor-
rectly assigning biopsies to the diagnostic groups. Com-
paring use of the three-antibody with the two-antibody
cocktail, diagnostic sensitivity was marginally improved
for the junior pathologist (76.4% vs 75.7%, respectively),
but was slightly lower for the senior pathologist (66.6% vs
77.4%, respectively). Although the explanation for this is
not clear, one likely possibility is that the senior patholo-
gist’s long experience with interpreting stains produced
with two-marker cocktails resulted in a paradoxical loss
of sensitivity when switching to a novel immunohisto-
chemical stain. Nonetheless, both pathologists showed a
marked improvement in the specificity of their various
diagnoses comparing the three-antibody with the two-
antibody cocktails (90.3% vs 71.8% specificity, respect-
ively, for the junior pathologist and 90.3% vs 68.7%
specificity, respectively, for the senior pathologist). The
reasons for this lower false negativity for the basal cell
markers in our study could be derived from previous
studies stating that CK 5/6 is preserved in the basal
cells of non-malignant glands that are cauterized, crushed
or distorted for various reasons including laboratory
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These findings are also comparable to the study by Ng
et al.; where 34βE12 was used and CK 5 was one of the
several high molecular weight keratins detected by anti-
body to 34βE12 [3].
Conclusions
Our study shows that CK5 is an useful supplementary
marker for identifying basal cells in prostate needle biop-
sies. Using CK5 in a three-antibody cocktail markedly
improves diagnostic specificity compared with a trad-
itional two-antibody immunohistochemical cocktail.
Whilst the findings from our small-sized study should
be confirmed in a larger independent study, our results
suggest that a three-marker cocktail containing anti-
bodies to AMACR, p63 and CK5 should be considered
for routine application in the evaluation of prostatic car-
cinoma in limited prostatic needle biopsies.
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